Neuroendocrine differentiation in prostate cancer: A sheep in wolf's clothing?

Nature Clinical Practice Urology

Volumn 3, Issue 3, 2006, Pages 138-144

  Slovin, Susan F ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Chromogranin A; Neuroendocrine differentiation; Prostate cancer; PSA

Indexed keywords

ADRENALIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FORSKOLIN; GONADORELIN AGONIST; INTERLEUKIN 6; IRINOTECAN; PROSTATE SPECIFIC ANTIGEN; TAXANE DERIVATIVE; VINBLASTINE; VINCRISTINE;

ANTIGEN DETECTION; CANCER CELL; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RESEARCH; CANCER RISK; CANCER THERAPY; DRUG RESPONSE; ETHNIC DIFFERENCE; GENE EXPRESSION; GENE FUNCTION; HORMONAL THERAPY; HUMAN; MALE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; NEUROENDOCRINOLOGY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RARE DISEASE; REVIEW; RISK ASSESSMENT; SEROLOGY; THROMBOCYTOPENIA;

CARCINOMA, NEUROENDOCRINE; HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 33644915843     PISSN: 17434270     EISSN: 17434289     Source Type: Journal    
DOI: 10.1038/ncpuro0435     Document Type: Review

References (44)

1. Amato K et al. (1992) Chemotherapy for small cell carcinoma of prostatic origin. J Urol 147: 935-937
2. Tetu B et al. (1987) Small cell carcinoma of the prostate: Part I-A clinicopathologic study of 20 cases. Cancer 59: 1803-1809
3. Oesterling JE et al. (1992) Small cell anaplastic carcinoma of the prostate: A clinical, pathological and immunohistochemical study of 27 patients. J Urol 147: 804-807
4. Howe MC et al. (2005) Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy. Histopathology 46: 195-201
5. Azzopardi JG and Evans DJ (1971) Argentaffin cells in prostatic carcinoma: Differentiation from lipofuscin and melanin in prostatic epithelium. J Pathol 104: 247-251
6. Pearse AG and Takor T (1979) Embryology of the diffuse neuroendocrine and its relationship to the common peptides. Fed Proc 38: 2288-2294
7. Schron DS et al. (1984) The histogenesis of small cell carcinoma of the prostate: An immunohistochemical study. Cancer 53: 2478-2480
8. Bostwick DG et al. (1994) Neuroendocrine differentiation in prostate intrapeithelial neoplasia and adenocarcinoma. Am J Surg Pathol 18: 1240-1246
9. Di Sant'Agnese PA (2001) Neuroendocrine differentiation in prostatic carcinoma: An update on recent developments. Ann Oncol 12 (Suppl): S135-S140
10. Di Sant'Agnese PA (2000) Divergent neuroendocrine differentiation in prostatic carcinoma. Sem Diagn Pathol 17: 149-161
11. Muzzonigro G and Galosi AB (2002) Biological selection criteria for radical prostatectomy. Ann NY Acad Sci 963: 204-212
12. Helpap B et al. (1999) Undifferentiated carcinoma of the prostate with small cell features: Immunohistochemical subtyping and reflections on histogenesis. Virchows Arch 434: 385-391
13. Helpap B et al. (1999) Neuroendocrine differentiation in prostate carcinomas: Histogenesis, biology, clinical relevance, and future therapeutic perspectives. Urol Int 62: 133-138
14. Bonkhoff H and Remberger K (1996) Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: A stem cell model. Prostate 28: 98-106
15. Bonkhoff H (1998) Neuroendocrine cells in benign and malignant prostate tissue morphogenesis, proliferation, and androgen receptor status. Prostate 8 (Suppl): S18-S22
16. Wang Q et al. (2004) Inhibitory effect of IL-6-induced neuroendocrine cells on prostate cancer cell proliferation. Prostate 61: 253-259
17. Algaba F et al. (1995) Neuroendocrine cells in peripheral prostatic zone: Age, prostatic intraepithelial neoplasia and latent cancer-related changes. Eur Urol 27: 329-333
18. Rubinstein JH et al. (1997) Small cell anaplastic carcinoma of the prostate: Seven new cases, review of the literature, and discussion of a therapeutic strategy. Am J Clin Oncol 20: 376-380
19. Vashchenko N and Abrahamsson PA (2005) Neuroendocrine differentiation in prostate cancer: Implications for new treatment modalities. Eur Urol 47: 147-155
20. Berruti A et al. (2005) Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone refractory disease. Endocr Relat Cancer 12: 109-117
21. Amorino GP and Parsons SJ (2004) Neuroendocrine cells in prostate cancer. Crit Rev Eukaryot Gene Expr 14: 287-300
22. Bostwick DG et al. (2002) Neuroendocrine expression in node positive prostate cancer: Correlation with systemic progression and patient survival. J Urol 168: 1204-1211
23. Daneshmand S et al. (2005) Ethnic differences in neuroendocrine cell expression in normal prostatic tissue. Urology 65: 1008-1012
24. Tokunaga M et al. (2005) Association of neuroendocrine differentiation with neoadjuvant hormone therapy effects in prostate cancer. Oncol Rep 13: 1081-1087
25. Iwamura M et al. (1998) Receptors for BPH growth factors are located in some neuroendocrine cells. Prostate 8 (Suppl): S14-S17
26. Wu JT et al. (1998) Serum chromogranin A: Early detection of hormonal resistance in prostate cancer patients. J Clin Lab Anal 12: 20-25
27. Cussenot O et al. (1996) Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol 155: 1340-1343
28. Syversen U et al. (2004) Clinical significance of elevated serum chromogranin A levels. Scand J Gastroenterol 39: 969-973
29. Sciarra A et al. (2003) Neuroendocrine differentiation in human prostatic tissue: Is it detectable and treatable. BJU Int 91: 438-445
30. Angelsen A et al. (1997) Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate. Prostate 31: 110-117
31. Birtle AJ and Freeman A (2003) Neuroendocrine differentiation in prostate cancer: Is it detectable and treatable? Br J Urol 92: 490-492
32. Cox ME et al. (1999) Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: Implications for prostate cancer progression. Cancer Res 59: 3821-3830
33. Di Sant'Agnese AP (1995) Neuroendocrine differentiation in prostatic carcinoma. Cancer 75 (Suppl): S1850-S1859
34. Wynick D and Bloom SR (1991) Clinical review 23: The use of long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors. J Clin Endocrinol Metab 73: 1-3
35. Kadar T et al. (1988) Receptors of prolactin, somatostatin, and luteinizing hormone-releasing in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing and somatostatin. Proc Natl Acad Sci USA 85: 890-894
36. Venkatesh PJ et al. (2004) Metastatic pure small-cell carcinoma of prostate. Am J Med Sci 328: 286-289
37. Papandreou CB et al. (2002) Results of phase II study with doxorubicin, etoposide and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 20: 3072-3080
38. Kelly WK et al. (1993) Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11: 607-615
39. Bonkhoff H and Fixemer T (2004) Neuroendocrine differentiation in prostate cancer. An unrecognized and therapy-resistant phenotype [German]. Urologe A 43: 836-842
40. Moore SR et al. (1992) Small cell carcinoma of the prostate: effectiveness of hormonal versus chemotherapy. Urology 39: 411-416
41. Sundin A et al. (2004) PET in the diagnosis of neuroendocrine tumors. Ann NY Acad Sci 1014: 246-257
42. Schwartz LH et al. (1998) Small cell and anaplastic prostate cancer: correlation between CT findings and prostate-specific antigen level. Radiology 208: 735-738
43. Matsumori N et al. (2004) An allograft model of androgen independent prostatic neuroendocrine carcinoma derived from a large probasin promoter-T antigen transgenic mouse line. J Urol 171: 439-442
44. True L (2004) Why we must better understand neuroendocrine differentiation in prostate cancer. J Urol 171: 443-444